Immunome Q3 net loss widens on higher expenses
IMNM•Immunome reported a third-quarter net loss of $85.78 million, with operating expenses of $90.36 million. It ended the quarter with $461.6 million in cash and expects to fund operations into 2028.
1. Quarterly results
Immunome reported a third-quarter net loss of $85.78 million and operating expenses of $90.36 million. Higher research and development spending, general and administrative costs, and share-based compensation contributed to the wider loss.
2. Cash and pipeline
The company ended the quarter with $461.6 million in cash and expects its current cash position to fund operations into 2028. Its lead drug, varegacestat, has an FDA target action date of April 28, 2027, and its marketing application has been validated by the EMA. Immunome plans to initiate an IM-1340 Phase 1 trial by year-end 2026.
